Clinical trials
Severe Hemophilia A clinical trials
Below are recruiting severe hemophilia a clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05802836Recruiting
Tracking an antibody response in severe hemophilia A on emicizumab
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
Frankfurt am Main, HesseAges Any age - NCT06703606RecruitingPhase 1
Switching from Emicizumab to Marstacimab for Severe Hemophilia A
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
Los Angeles, CaliforniaAges 12–74 - NCT04817462Recruiting
Liver biopsy in people with haemophilia gene therapy
This study takes a small liver tissue sample (a liver biopsy) in men who previously received haemophilia gene therapy. The goal is to learn more about how the gene therapy works and how safe it is for the liver.
LondonAges 18–80 - NCT07226206RecruitingPhase 1/Phase 2
Gene therapy for adults with severe hemophilia A
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
Orange, CaliforniaAges 18 years+ - NCT07080905RecruitingPhase 3
Gene therapy for teens with severe hemophilia B
This trial tests a single dose of CSL222, a gene therapy, in adolescent boys with severe or moderately severe hemophilia B. The goal is to see if it can reduce or eliminate the need for regular factor IX infusions.
Orange, CaliforniaAges 11.5 years–17.2 years - NCT07414511Recruiting
Hemophilia A research study for pregnant families
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Seattle, WashingtonAges Any age - NCT04131036Recruiting
Compare emicizumab and factor VIII for joint and bone health
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
Los Angeles, CaliforniaAges 16 years+ - NCT07314983Recruiting
Long-term blood thinning in severe hemophilia A
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
StrasbourgAges 18 years+ - NCT05981274Recruiting
Bone health study of a long-acting factor VIII for hemophilia A
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Taipei, Neihu Dist.Ages Any age - NCT05987449RecruitingPhase 1/Phase 2
Study of NXT007 for severe or moderate hemophilia A
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
Sacramento, CaliforniaAges 2–59 - NCT06320626RecruitingPhase 4
Personalized emicizumab dosing for hemophilia A
This trial tests whether adjusting emicizumab (Hemlibra) doses based on your body's drug levels can safely maintain good bleed control in people with hemophilia A who have been on the drug for at least a year.
Nijmegen, GelderlandAges 1 year+ - NCT06816953Enrolling by invitation
Joint health in severe hemophilia A with prophylaxis
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
Bangkok, PatumwanAges Any age - NCT06145373RecruitingPhase 4
Fitusiran for preventing bleeds in severe hemophilia A
This study tests a new medicine called fitusiran to help prevent bleeding episodes in people with severe hemophilia A who are already receiving emicizumab. It may offer an additional treatment option for those with or without inhibitors.
Los Angeles, CaliforniaAges 12 years+ - NCT05022459Recruiting
Prevent bleeding in kids with Hemophilia A who play sports
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Little Rock, ArkansasAges 6–19 - NCT05768386Enrolling by invitation
Long-term follow-up for severe hemophilia A after BMN 270 study
This study checks how people with severe hemophilia A are doing over time after joining a previous BioMarin study of BMN 270. It helps researchers understand long-term safety and outcomes and may support your ongoing care plan.
Los Angeles, CaliforniaAges 18 years+ - NCT06938542Enrolling by invitation
Palliative care needs for kids with rare diseases
This study asks children with rare diseases and their families about what kind of palliative care (comfort and support) they need. It aims to understand how to better help families through their child's illness.
Washington D.C., District of ColumbiaAges 1–99 - NCT05935358RecruitingPhase 4
Nuwiq added around surgery for people with hemophilia A
This Phase 4 study looks at how well Nuwiq works to manage bleeding risk around the time of major elective surgery in people with severe hemophilia A who already take emicizumab to prevent bleeds. It may help your surgical team plan safer blood-clotting support during and after surgery.
Dallas, TexasAges 12 years+ - NCT06142552RecruitingPhase 3
Study of a longer-lasting hemophilia A treatment for men
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
BeijingAges 12–65 - NCT07684898RecruitingPhase 3
Long-acting factor VIII for severe hemophilia A
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT07663903RecruitingPhase 3
New longer-lasting factor VIII for severe hemophilia A (on-demand use)
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT07096349Recruiting
Chronic pain study in severe hemophilia A
This study looks at chronic pain in people with severe hemophilia A. It aims to understand pain better through questionnaires and joint health checks.
Oviedo, Principality of AsturiasAges 18 years+ - NCT05500807RecruitingPhase 1
Emicizumab study for severe von Willebrand disease or overlap disorder
This Phase 1 trial studies how well and safely emicizumab works for people with severe von Willebrand disease (VWD) or VWD plus hemophilia A. Emicizumab is a preventive medicine given regularly to reduce bleeding risk.
Orange, CaliforniaAges birth–90 years
Hear when a new Severe Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for severe hemophilia a?
- Yes. Clin2 currently lists 22 recruiting severe hemophilia a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a severe hemophilia a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a severe hemophilia a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.